Učitavanje...
Uveal Effusion After Immune Checkpoint Inhibitor Therapy
IMPORTANCE: Immune checkpoint inhibitors, including antiprogrammed cell death protein-1 (anti-PD-1) and antiprogrammed cell death ligand-1 (anti-PD-L1) monoclonal antibodies, have recently been introduced as a promising new immunotherapy for solid cancers. The adverse effects typically include infla...
Spremljeno u:
| Izdano u: | JAMA Ophthalmol |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Medical Association
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6145660/ https://ncbi.nlm.nih.gov/pubmed/29677240 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaophthalmol.2018.0920 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|